Floatz Rating
CCC51/100
Confidence
Indicative
Sponsor
National Institute of Mental Health (NIMH)
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06511908CT.gov Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| (2R,6R)-HYDROXYNORKETAMINE (this asset) | National Institute of Mental Health (NIMH) | P2 | CCC · 51 |
| Brexpiprazole | Dr. Albert Kar-Kin Chung | P4 | A |
| Jnj-54135419 | Chinese PLA General Hospital | P4 | BBB |
| Saredutant | Sanofi | P3 | BBB |
| Lithium, Elemental | Rakitzi, Stavroula | P4 | BBB |
| Escitalopram | Poznan University of Medical Sciences | P4 | BBB |
| VENLOR | Janssen Research & Development, LLC | P4 | BBB |
| Fluoxetine | University of Oxford | P4 | BBB |
| Paroxetine | Brigham and Women's Hospital | P4 | BBB |
+42 more in the Depressive Disorder cohort
Other indications for (2R,6R)-HYDROXYNORKETAMINE
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mental Disorder | — | P2 | CCC · 52 |
| Mood Disorder | — | P2 | CCC · 52 |
| Major Depressive Disorder | — | P2 | CCC · 49 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. (2R,6R)-HYDROXYNORKETAMINE in Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/2r6r-hydroxynorketamine-depressive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →